Hemophilia A gene therapy superior to FVIII replacement in Phase 3 trial
Giroctocogene fitelparvovec, an investigational gene therapy for adults with hemophilia A, is generally well tolerated and superior to standard replacement therapy in reducing bleeds, according to new top-line results from a Phase 3 clinical trial. The open-label trial, dubbed AFFINE (NCT04370054) and sponsored by Pfizer, has…